eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical
When enzymes escape the cell, they can do remarkable things.
When enzymes escape the cell, they can do remarkable things. That is the bet eXoZymes (NASDAQ: EXOZ) has been building on since it spun out of Jim Bowie's lab at UCLA in 2019 — and a new result from independent partner Cayman Chemical suggests the bet is starting to pay off at commercial scale.
Cayman ran eXoZymes' cell-free biomanufacturing protocol at 100 liters — a 100-fold scale-up from the 1-liter starting point — and produced more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity. The reaction ran through real-world pH drift and precipitation events that typically derail enzyme-based manufacturing. It held. Cayman ran the reaction, downstream processing, and analysis entirely on its own.
"From the first sample, the analysis showed over a 99% conversion rate." Patrick Westcott, director of catalog chemistry production at Cayman, said he took a second sample to make sure the result was real. "We were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale-up of their process. That was very much an aha moment for us."
That "aha" moment is the thing the cell-free biomanufacturing field has been chasing for years. Cell-based systems — the workhorses of industrial biotech — carry metabolic overhead: the host cell's own biology competes with the pathway you are trying to run, resources get diverted, and when you scale up, the system changes enough that it becomes a different problem. Enzyme engineers call this the "black hole of scale-up." Cell-free approaches sidestep it by pulling the relevant enzymes out of cells entirely and running them in a defined reaction environment. The tradeoff has traditionally been cost: without the cell to maintain and reproduce the enzymes, you need higher concentrations and more expensive downstream processing to reach competitive yields.
eXoZymes' pitch is that its AI-optimized enzyme design — it calls them exozymes — gets around that tradeoff. The company's platform engineers and screens enzymes computationally before running them, selecting variants optimized to function in the cell-free environment. The result, according to its internal data and now a third-party validation, is a system that can scale without the usual efficacy cliff.
The company's origins are worth knowing for context on how it got here. eXoZymes launched as Invizyne Technologies in 2019, licensing the UCLA lab's technology with $5.9M in seed funding from MDB Capital. Michael Heltzen took over as CEO in early 2025 following a leadership transition, with MDB Capital founder Christopher Marlett becoming chairman. The company listed on Nasdaq later that year. Since then it has collected a $3M NSF grant to develop a modular cell-free power plant architecture, a $2M BioMADE Department of Defense grant for isobutanol enzyme production, and been named a core industry partner in a $9M NSF-funded initiative on modular cell-free biomanufacturing.
The compound Cayman produced — NCT — is not random. N-trans-caffeoyltyramine is a phenolic amide found in plants like hemp and tomatoes, and it has attracted growing interest for its role in gut barrier function, liver fat metabolism, and mitochondrial activity. eXoZymes and its spinout subsidiary NCTx have positioned NCT as their beachhead product precisely because it carries GRAS (generally recognized as safe) status for functional foods, which significantly shortens the path to market in food and supplement channels while keeping pharmaceuticals in view. In a July 2025 lab-scale run, the company produced 4 grams at greater than 99% purity; the Cayman run represents roughly a 125-fold increase in batch volume, with purity holding near the same level.
The 500 grams now available is not a commercial batch — it is a calling card. eXoZymes is using it to supply material under evaluation and formulation development agreements with partners. The company has said it expects to be in tech transfer to GMP pilot production next year, with kilogram-scale partner demand in 2026 and ton-scale ambitions beyond that. With more than 100 active partnership discussions and NDAs signed across pharma, nutraceuticals, and specialty chemicals, the commercial pipeline is real — though early-stage.
The bigger question is whether this result signals that cell-free biomanufacturing is graduating from lab curiosity to viable manufacturing paradigm. The field has produced impressive academic results for over a decade while struggling to close the gap with cell-based systems on cost and scale. eXoZymes' third-party validation — run by a respected contract manufacturer on equipment it owns — is a meaningfully different kind of evidence than an internal benchmark. Whether the economics hold at the multi-hundred-liter or kiloliter scale the company would need for real commercial demand remains to be seen. But Cayman's Westcott, a veteran of cell-based enzymatic biocatalysis, appears persuaded.
"Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether." His quote in eXoZymes' announcement is notable precisely because it comes from someone who has watched that transition fail many times. If cell-free biomanufacturing has a breakout year, this result will be the footnote that explained why.
Sources:
